Patents by Inventor Songnian Lin

Songnian Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170248580
    Abstract: Methods for identifying drug-saccharide conjugates that bind the mannose receptor, C type 1, (MRC1) and may be taken up by cells expressing MRC1, and the use of such drug-saccharide conjugates for treatment of particular diseases are described. In particular, the methods for identifying insulin-saccharide conjugates that bind the MRC1 receptor and may be taken up by cells expressing the MRC1 and use of such conjugates for treatment of diabetes are described.
    Type: Application
    Filed: May 15, 2017
    Publication date: August 31, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Yingjun Mu, Ruojing Yang, Xinghai Li, Margaret Wu, Qing Dallas-yang, Yuli Chen, Ge Dai, Songnian Lin, David E. Kelley, Mark Erion
  • Publication number: 20170216250
    Abstract: Use of a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor for the treatment of diabetes and related conditions is disclosed.
    Type: Application
    Filed: April 11, 2017
    Publication date: August 3, 2017
    Applicant: Merch Sharp & Dohme Corp.
    Inventors: Hong-Ping Guan, Jose M. Castro-Perez, Harry R. Davis, Samuel E. Engel, Douglas G. Johns, Songnian Lin, Stephen F. Previs, Thomas P. Roddy, Liangsu Wang, Sheng-Ping Wang, Yusheng Xiong
  • Patent number: 9649294
    Abstract: Glucagon receptor antagonist compounds are disclosed which are of long duration of action. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: May 16, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Libo Xu, Emma R. Parmee, Xibin Liao
  • Publication number: 20170107268
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Application
    Filed: November 19, 2015
    Publication date: April 20, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
  • Patent number: 9527838
    Abstract: Novel pyridine-2-carboxamide derivatives of formula I and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are effective as glucokinase activating agents. Pharmaceutical compositions and methods of treatment are also included. The present invention relates to novel pyridine-2-carboxamide derivatives and salts thereof which are effective as glucokinase activating agents. Moreover, it relates to compositions containing such compounds, and methods of treatment.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: December 27, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Emma R. Parmee, Jiayi Xu
  • Publication number: 20160303244
    Abstract: Insulin conjugates comprising an insulin molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein the saccharide for at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.
    Type: Application
    Filed: June 24, 2016
    Publication date: October 20, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Lin Yan, Ahmet Kekec, Yuping Zhu, David N. Hunter, Pei Huo, Danqing Feng, Ravi P. Nargund, Christopher R. Moyes, Zhiqiang Zhao, Brenda Pipik, Dmitri Pissarnitski, Joseph L. Duffy, Erin N. Guidry
  • Patent number: 9453038
    Abstract: Novel pyridine-2-carboxamide derivatives of formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are effective as glucokinase activating agents. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: September 27, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Rui Zhang, Brian Campbell, Sunita V. Dewnani, Jiayi Xu, Libo Xu, Emma R. Parmee, Roman Kats-Kagan
  • Publication number: 20160251407
    Abstract: Insulin conjugates comprising an insulin molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.
    Type: Application
    Filed: October 2, 2014
    Publication date: September 1, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Lin Yan, Ahmet Kekec, Yuping Zhu, David N. Hunter, Pei Huo, Danqing Feng, Ravi P. Nargund, Christopher R. Moyes, Zhiqiang Zhao, Brenda Pipik, Dmitri Pissarnitski, Joseph L. Duffy, Erin Guidry
  • Publication number: 20160250184
    Abstract: Glucagon receptor antagonist compounds are disclosed which are of long duration of action. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Application
    Filed: October 30, 2014
    Publication date: September 1, 2016
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: SONGNIAN LIN, Libo Xu, Emma R. Parmee, Xibin Liao
  • Patent number: 9427475
    Abstract: Insulin conjugates comprising an insulin molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein the saccharide for at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: August 30, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Lin Yan, Pei Huo
  • Patent number: 9359339
    Abstract: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: June 7, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Fengqi Zhang, Emma R. Parmee, Sunita V. Dewnani
  • Publication number: 20150336946
    Abstract: Novel pyridine-2-carboxamide derivatives of formula I and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are effective as glucokinase activating agents. Pharmaceutical compositions and methods of treatment are also included. The present invention relates to novel pyridine-2-carboxamide derivatives and salts thereof which are effective as glucokinase activating agents. Moreover, it relates to compositions containing such compounds, and methods of treatment.
    Type: Application
    Filed: December 12, 2013
    Publication date: November 26, 2015
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Songnian Lin, Emma R. Parmee, Jiayi Xu
  • Publication number: 20150336991
    Abstract: Novel pyridine-2-carboxamide derivatives of formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are effective as glucokinase activating agents. Pharmaceutical compositions and methods of treatment are also included.
    Type: Application
    Filed: December 12, 2013
    Publication date: November 26, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Rui Zhang, Brian Campbell, Sunita V. Dewnani, Jiayi Xu, Libo Xu, Emma R. Parmee, Roman Kats-Kagan
  • Publication number: 20150320724
    Abstract: Use of a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor for the treatment of diabetes and related conditions is disclosed.
    Type: Application
    Filed: December 8, 2013
    Publication date: November 12, 2015
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Hong-Ping Guan, Jose M. Castro-Perez, Harry R. Davis, Samuel E. Engel, Douglas G. Johns, Songnian Lin, Stephen F. Previs, Thomas P. Roddy, Liangsu Wang, Sheng-Ping Wang, Yusheng Xiong
  • Publication number: 20150105317
    Abstract: Insulin conjugates comprising an insulin molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein the saccharide for at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.
    Type: Application
    Filed: October 2, 2014
    Publication date: April 16, 2015
    Inventors: Songnian Lin, Lin Yan, Ahmet Kekec, Yuping Zhu, David N. Hunter, Pei Huo, Danqing Feng, Ravi P. Nargund, Christopher R. Moyes, Zhiqiang Zhao, Brenda Pipik, Dmitri Pissarnitski, Joseph L. Duffy, Erin N. Guidry
  • Publication number: 20150018399
    Abstract: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Application
    Filed: August 5, 2014
    Publication date: January 15, 2015
    Inventors: SONGNIAN LIN, Fengqi Zhang, Emma R. Parmee, Sunita V. Dewnani
  • Patent number: 8809579
    Abstract: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: August 19, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Roman Kats-Kagan, Christian P. Stevenson, Xibin Liao, Qinghong Fu, Emma R. Parmee, Songnian Lin
  • Patent number: 8445538
    Abstract: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: December 9, 2009
    Date of Patent: May 21, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Xibin Liao, Roman Kats-Kagan, John E. Stelmach, Emma R. Parmee
  • Patent number: 8436015
    Abstract: Glucagon receptor antagonist compounds of formula I are disclosed: The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: September 10, 2009
    Date of Patent: May 7, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Christian P. Stevenson, Emma R. Parmee, Libo Xu, Xibin Liao, Edward Metzger, Rui Liang, Fengqi Zhang, John E. Stelmach
  • Patent number: 8399507
    Abstract: Tricyclic compounds containing a cyclopropanecarboxylic acid fused to a bicyclic ring, including pharmaceutically acceptable salts, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: March 19, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Gui-Bai Liang, Xibin Liao, Weiguo Liu, Paul E. Finke, Dooseop Kim, Lihu Yang, Songnian Lin